Gynuity Health Projects


Resources by Last Update



List of Mifepristone Approvals

Map of Mifepristone Approvals



Abortion With Self-Administered Misoprostol: A Guide For Women


Postpartum Hemorrhage Program Brief


Preeclampsia Program Brief



Contraception Program Brief


Misoprostol for Prevention of Postpartum Hemorrhage




Map of Misoprostol Approvals



Misoprostol for Early Abortion

Infectious Disease Program Brief



Medical Abortion Program Brief



Misoprostol for Treatment of Postpartum Hemorrhage



Medical Abortion Guidebook


Pregnancy Failure and Miscarriage Program Brief


Fever after treatment of postpartum hemorrhage

Blood Loss After Vaginal Delivery

Misoprostol for the Treatment of Postpartum Hemorrhage: Findings from Clinical Research Trials



Misoprostol for Incomplete Abortion and Miscarriage

Advance misoprostol distribution for preventing and treating postpartum haemorrhage

What Is the Most Effective, Low-Cost Method for Inducing Labor in Women With Pre-Eclampsia?

Results of a pilot study in the U.S. and Vietnam to assess the utility and acceptability of a MLPT

Postpartum Hemorrhage Prevention in Nepal: A Program Assessment

Improving Care at Delivery for Women with Preeclampsia

Foley catheterisation versus oral misoprostol for induction of labour in hypertensive women in India

Postpartum Hemorrhage Prevention in Nepal

FAQs on the Use of Multilevel Pregnancy Tests for Medical Abortion

Sixteen Years of Overregulation: Time to Unburden Mifeprex

Dissemination and implementing a core outcome set for medical and surgical abortion

Medical abortion

Serial Multilevel Urine Pregnancy Testing to Assess Medical Abortion Outcome

Sexual violence-related pregnancies in eastern Democratic Republic of Congo

Misoprostol-induced fever and genetic polymorphisms in drug transporters

800μg misoprostol and mucosal and systemic immune activation or the cervicovaginal microbiome

Second trimester MA with mifepristone followed by unlimited dosing of buccal misoprostol in Armenia

Two prophylactic medication approaches in addition to a pain control regimen for early MA

Simultaneous Administration Compared With a 24-Hour Mifepristone-Misoprostol Interval

Effects of Depot Medroxyprogesterone Acetate Injection Timing on MA Efficacy and Repeat Pregnancy

Home use of mifepristone and misoprostol for MA up to 10weeks of pregnancy in Kazakhstan

Self-administered multi-level pregnancy tests in simplified follow-up of medical abortion in Tunisia

Acceptability & feasibility of 400μg buccal misoprostol after 200 mg mife for early MA in Georgia

Innovative research at the 2016 National Abortion Federation Annual Meeting

Prospective study of home use of mifepristone and misoprostol for medical abortion up to 10weeks

Oxytocin via Uniject versus oral misoprostol for prevention of postpartum haemorrhage

Determining early medical abortion outcomes at 3, 7 and 14 days after mifepristone

A crossover pharmacokinetic study of misoprostol by the oral, sublingual and buccal routes

Is It Safe to Provide Abortion Pills Over The Counter?

Increasing Access to Abortion With Telemedicine

The MamaMiso study of self-administered misoprostol to prevent bleeding after childbirth in Uganda

A double-blind randomized controlled trial of mifepristone or placebo before buccal misoprostol

PRE-EMPT (PREeclampsia-Eclampsia Monitoring, Prevention and Treatment)

Vaginal and Rectal Clostridium sordellii and Clostridium perfringens Presence Among Women in the US

Effect of Immediate Compared with Delayed Insertion of Etonogestrel Implants

Magnesium sulphate for prevention of eclampsia: are intramuscular & intravenous regimens equivalent?

Induction of labour in preeclamptic women: a randomised trial comparing the Foley balloon catheter

Home use of urine pregnancy tests for medical abortion follow-up

A prospective, non-randomized study of home-use of mifepristone for medical abortion in the U.S.

Adjunct mifepristone for cervical preparation prior to dilation and evacuation: a randomized trial

Continuing pregnancy after mifepristone and “reversal” of first-trimester medical abortion

Misoprostol Added to WHO Model List of Essential Medicines for Treatment of Incomplete Abortion and

Preventing postpartum hemorrhage at the community level

Treatment for primary postpartum haemorrhage

How effective are the components of active management of the third stage of labor?

A systematic review of the relationship between blood loss and clinical signs.

Misoprostol for primary versus secondary prevention of postpartum haemorrhage

Oxytocin in Uniject™ versus misoprostol for prevention of postpartum hemorrhage at the community

Outpatient medical abortion is safe and effective through 70 days gestation

Early Medical Abortion without Prior Ultrasound

If we can do it for misoprostol, why not for mifepristone?

Cervical Preparation Before Dilation and Evacuation Using Adjunctive Misoprostol or Mifepristone

Off-label indications for mifepristone in gynecology and obstetrics

Reaching women where they are

Mifepristone label laws and trends in use: recent experiences in four US states

Youth Issues in Reproductive Health

Women’s Health


Reproductive Tract Cancers

Pregnancy Termination/Abortion

Pregnancy, Delivery, and Post-Natal Care



Infectious Disease

Female Genital Mutilation

Family Planning

Emergency Contraceptives

Child Health

Breast Cancer

Fifteen years: looking back and looking forward

Secondary Prevention/Early Treatment of PPH

Misoprostol added to the WHO Model List of Essential Medicines for the Treatment of PPH

Hormonal contraceptive methods and risk of HIV acquisition in women

Knowledge of Abortion Laws and Services among Low-Income Women in Three United States Cities

Is One Of These Things Not Just Like The Other? Why Abortion can’t be Separated from Contraception

What happens when we routinely give doxycycline to medical abortion patients?

Phone follow-up with SQPT after medical abortion in Moldova and Uzbekistan

The introduction of first trimester medical abortion in Armenia

Safety, efficacy and acceptability of outpatient mifepristone-misoprostol MA through 70 days

A prospective open-label study of home use of mifepristone for medical abortion in Nepal

WHO Multicountry Survey on Maternal and Newborn Health Research Network

DMPA and HIV: do we need a trial?